摘要
目的:检测非小细胞肺癌(NSCLC)中转化生长因子βⅡ型受体(TGFBR2)的表达,并探讨其表达的变化与NSCLC的发生的相关性及与临床病理因素的关系。方法:采用组织芯片技术和免疫组化方法,检测115对原发性NSCLC(腺癌50例,鳞癌44例,腺鳞癌6例,巨细胞癌2例,大细胞癌13例)及其相应正常对照肺组织中TGFBR2蛋白的表达情况。结果:TGFBR2在NSCLC与正常对照组织中的表达差异有统计学意义(P<0.01),大细胞癌与腺癌、鳞癌等病理类型的表达水平差异有统计学意义(P<0.05),但TGFBR2的表达变化与患者年龄、性别、肿瘤大小和局部侵袭、淋巴结侵袭、转移、临床分期差异无统计学意义(P>0.05)。结论:TGFBR2的表达异常与病理类型有关,TGFBR2的表达下调可能与NSCLC尤其是大细胞癌的发生或发展相关。
Objective： To evaluate the expression of transforming growth factor beta type ]I receptor （TGFBR2） in non-small cell lung cancer （NSCLC） and to explore the associations of TGFBR2 expression with NSCLC occurrence and clinical pathological features. Methods： Tissue microarray and immunohistochemistry were used to detect the expression of TGFBR2 in 115 matched-pairs of primary non-small cell lung cancer （NSCLC） samples （50 of adenocarcinoma, 44 of squamous cell carcinoma, 6 of adenosquamous carcinoma, 2 of giant cell carcinoma and 13 of large cell carcinoma） and normal lung tissues. Results： Significant difference in TGFBR2 expression was noted between NSCLC samples and normal controls （ P 〈 0.01 ） , and also among samples of large cell carcinoma, adenocarcinoma and squamous carcinoma （P 〈 0.05）. TGFBR2 expression was not statistically correlated with age, gender, tumor size, local invasion, lymph node involvement, metastasis and TNM stage （ P 〉 0.05 ）. Conclusion ： The altered expression of TGFBR2 may be related with tumor pathology. Down-regulated expression of TGFBR2 is probably linked to development and progression of NSCLC, large cell carcinoma in particular.
出处
《广州医学院学报》
2011年第4期38-43,共6页
Academic Journal of Guangzhou Medical College
基金
上海市自然科学基金(07ZRl4145)
关键词
非小细胞肺癌
转化生长因子βⅡ型受体
组织芯片
表达下调
non-small cell lung cancer
transforming growth factor beta type receptor
tissuernicroarray
down-regulated expression
